Loading...

Kewaunee Scientific

Nasdaq:KEQU
Snowflake Description

Excellent balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KEQU
Nasdaq
$51M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The last earnings update was 4 days ago. More info.


Add to Portfolio Compare Print
KEQU Share Price and Events
7 Day Returns
0.3%
NasdaqGM:KEQU
-0.5%
US Medical Equipment
0.8%
US Market
1 Year Returns
-44.4%
NasdaqGM:KEQU
14.6%
US Medical Equipment
4.8%
US Market
KEQU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kewaunee Scientific (KEQU) 0.3% -16.3% -14.4% -44.4% -2.4% 5.8%
US Medical Equipment -0.5% 3.1% 6.4% 14.6% 62% 103.5%
US Market 0.8% 4.3% 2.8% 4.8% 37.9% 43.5%
1 Year Return vs Industry and Market
  • KEQU underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • KEQU underperformed the Market in United States of America which returned 4.8% over the past year.
Price Volatility
KEQU
Industry
5yr Volatility vs Market
Related Companies

KEQU Value

 Is Kewaunee Scientific undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kewaunee Scientific. This is due to cash flow or dividend data being unavailable. The share price is $18.6175.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kewaunee Scientific's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kewaunee Scientific's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:KEQU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-04-30) in USD $0.56
NasdaqGM:KEQU Share Price ** NasdaqGM (2019-07-15) in USD $18.62
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 40.99x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kewaunee Scientific.

NasdaqGM:KEQU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:KEQU Share Price ÷ EPS (both in USD)

= 18.62 ÷ 0.56

33.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kewaunee Scientific is good value based on earnings compared to the US Medical Equipment industry average.
  • Kewaunee Scientific is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Kewaunee Scientific's expected growth come at a high price?
Raw Data
NasdaqGM:KEQU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 33.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
14.3%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kewaunee Scientific, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kewaunee Scientific's assets?
Raw Data
NasdaqGM:KEQU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-04-30) in USD $17.15
NasdaqGM:KEQU Share Price * NasdaqGM (2019-07-15) in USD $18.62
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.34x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqGM:KEQU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:KEQU Share Price ÷ Book Value per Share (both in USD)

= 18.62 ÷ 17.15

1.09x

* Primary Listing of Kewaunee Scientific.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kewaunee Scientific is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Kewaunee Scientific's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Kewaunee Scientific has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

KEQU Future Performance

 How is Kewaunee Scientific expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

  • No analysts cover Kewaunee Scientific, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kewaunee Scientific expected to grow at an attractive rate?
  • Kewaunee Scientific's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Kewaunee Scientific's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Kewaunee Scientific's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:KEQU Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:KEQU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 14.3%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:KEQU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:KEQU Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-04-30 159 1
NasdaqGM:KEQU Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-04-30 147 2 2
2019-01-31 156 8 4
2018-10-31 162 8 5
2018-07-31 166 0 5
2018-04-30 158 3 5
2018-01-31 148 5 5
2017-10-31 140 7 5
2017-07-31 135 12 4
2017-04-30 139 12 5
2017-01-31 138 10 4
2016-10-31 140 8 5
2016-07-31 135 6 4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kewaunee Scientific's earnings are expected to grow by 14.3% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Kewaunee Scientific is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:KEQU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Kewaunee Scientific Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KEQU Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-04-30
NasdaqGM:KEQU Past Financials Data
Date (Data in USD Millions) EPS *
2019-04-30 0.56
2019-01-31 1.53
2018-10-31 1.88
2018-07-31 2.00
2018-04-30 1.94
2018-01-31 1.90
2017-10-31 1.70
2017-07-31 1.61
2017-04-30 1.67
2017-01-31 1.65
2016-10-31 1.84
2016-07-31 1.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kewaunee Scientific will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kewaunee Scientific's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kewaunee Scientific has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

KEQU Past Performance

  How has Kewaunee Scientific performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kewaunee Scientific's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kewaunee Scientific's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Kewaunee Scientific's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Kewaunee Scientific's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.
Earnings and Revenue History
Kewaunee Scientific's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kewaunee Scientific Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KEQU Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-04-30 146.55 1.53 23.00
2019-01-31 156.31 4.20 23.61
2018-10-31 162.13 5.14 24.27
2018-07-31 166.32 5.45 23.56
2018-04-30 158.05 5.28 22.93
2018-01-31 148.12 5.17 21.94
2017-10-31 140.30 4.60 20.56
2017-07-31 135.16 4.36 20.12
2017-04-30 138.56 4.52 20.07
2017-01-31 138.07 4.46 19.33
2016-10-31 140.11 4.95 19.03
2016-07-31 134.82 4.16 18.09
2016-04-30 128.63 3.80 17.33
2016-01-31 124.82 3.07 16.86
2015-10-31 120.16 2.73 16.44
2015-07-31 119.38 3.24 16.51
2015-04-30 118.83 3.53 16.54
2015-01-31 115.60 3.90 16.56
2014-10-31 113.86 4.02 16.46
2014-07-31 109.70 3.54 16.27
2014-04-30 111.17 3.90 16.07
2014-01-31 115.92 4.13 16.45
2013-10-31 117.35 4.07 16.73
2013-07-31 122.44 4.00 16.99
2013-04-30 117.12 3.04 16.98
2013-01-31 114.31 3.08 16.70
2012-10-31 108.43 2.42 16.63
2012-07-31 103.21 1.64 16.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Kewaunee Scientific has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Kewaunee Scientific used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • Kewaunee Scientific's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Kewaunee Scientific's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kewaunee Scientific has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

KEQU Health

 How is Kewaunee Scientific's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kewaunee Scientific's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kewaunee Scientific is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kewaunee Scientific's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kewaunee Scientific's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kewaunee Scientific Company Filings, last reported 2 months ago.

NasdaqGM:KEQU Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-04-30 47.70 10.93 10.65
2019-01-31 49.51 6.83 10.77
2018-10-31 49.38 6.66 9.48
2018-07-31 48.40 9.67 9.06
2018-04-30 48.19 6.32 9.72
2018-01-31 46.09 7.50 9.18
2017-10-31 45.32 10.73 11.79
2017-07-31 44.19 6.78 12.02
2017-04-30 43.26 6.94 12.51
2017-01-31 40.72 8.13 8.25
2016-10-31 40.75 10.28 7.58
2016-07-31 39.66 10.62 6.71
2016-04-30 38.55 7.59 5.22
2016-01-31 36.79 9.41 3.71
2015-10-31 36.47 9.51 3.27
2015-07-31 35.81 8.99 2.90
2015-04-30 35.20 9.15 3.04
2015-01-31 36.19 5.33 3.86
2014-10-31 36.09 5.34 4.86
2014-07-31 35.28 9.72 4.37
2014-04-30 34.22 7.76 6.25
2014-01-31 31.85 8.89 6.66
2013-10-31 31.57 7.54 5.28
2013-07-31 31.01 10.06 4.41
2013-04-30 33.69 10.46 5.81
2013-01-31 32.70 6.22 4.20
2012-10-31 32.61 9.26 5.88
2012-07-31 31.97 10.12 7.72
  • Kewaunee Scientific's level of debt (22.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (22.7% vs 22.9% today).
  • Debt is well covered by operating cash flow (22.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6.3x coverage).
X
Financial health checks
We assess Kewaunee Scientific's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kewaunee Scientific has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

KEQU Dividends

 What is Kewaunee Scientific's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.08%
Current annual income from Kewaunee Scientific dividends.
If you bought $2,000 of Kewaunee Scientific shares you are expected to receive $82 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Kewaunee Scientific's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.41%).
  • Kewaunee Scientific's dividend is above the markets top 25% of dividend payers in United States of America (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:KEQU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:KEQU Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-04-30
NasdaqGM:KEQU Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-05-29 0.760 3.830
2018-11-20 0.760 3.039
2018-08-29 0.760 2.533
2018-05-30 0.680 2.017
2018-02-28 0.680 2.088
2017-11-21 0.680 2.395
2017-08-30 0.680 2.388
2017-05-31 0.600 2.438
2016-11-22 0.600 2.510
2016-08-31 0.600 2.571
2016-06-01 0.520 2.657
2016-03-02 0.520 3.125
2015-11-24 0.520 3.075
2015-08-26 0.520 3.125
2015-06-02 0.480 2.853
2015-03-04 0.480 2.810
2014-11-25 0.480 2.705
2014-08-27 0.480 2.713
2014-08-26 0.440 2.401
2014-05-28 0.440 2.523
2014-03-05 0.440 2.668
2013-11-26 0.440 2.713
2013-08-28 0.440 2.575
2013-05-29 0.400 3.028
2013-02-26 0.400 3.073
2012-11-28 0.400 3.266
2012-08-21 0.400 3.502
2012-05-30 0.400 3.740
2012-02-29 0.400 4.759
2011-11-30 0.400 4.640
2011-08-24 0.400 4.454
2011-05-31 0.400 4.095
2011-03-02 0.400 3.612
2010-11-22 0.400 2.960
2010-08-25 0.400 3.609
2010-06-01 0.400 3.527
2010-02-25 0.400 2.966
2009-11-23 0.400 2.726
2009-08-26 0.400 2.844
2009-05-27 0.320 2.877
2009-02-26 0.320 3.560
2008-11-24 0.320 3.634
2008-08-27 0.320 3.149

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Kewaunee Scientific's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.8x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kewaunee Scientific's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kewaunee Scientific afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kewaunee Scientific has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

KEQU Management

 What is the CEO of Kewaunee Scientific's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Hull
COMPENSATION $516,745
AGE 43
TENURE AS CEO 0.3 years
CEO Bio

Mr. Thomas D. Hull, III, has been President and Chief Executive Officer at Kewaunee Scientific Corporation since March 11, 2019 and served as its Chief Financial Officer since November 1, 2015 until April 29, 2019. Mr. Hull has been Director at Kewaunee Scientific Corporation since March 2019. Mr. Hull served as Vice President of Finance, Secretary and Treasurer of Kewaunee Scientific Corp. since November 1, 2015 and November 2, 2015 respectively until March 11, 2019. Since 2011, Mr. Hull has been Vice President of Finance, Accounting and Information Technology with ATI Specialty Materials, in Charlotte, North Carolina. Mr. Hull held several management positions with Ernst & Young in Pittsburgh, Pennsylvania and Charlotte, North Carolina from 1998 to 2011.  Mr. Hull served as a Director of Kewaunee Scientific Corp. since November 2, 2015. He is a member of the American Institute of Certified Public Accountants (AICPA), Pennsylvania Institute of Certified Public Accountants (PICPA), and North Carolina Society of Certified Public Accountants (NCCPA). Mr. Hull is a Certified Public Accountant and has a Master of Business Administration from the University of Pittsburgh, Joseph M. Katz School of Business and a Bachelor of Science degree in Accounting from LaRoche College.

CEO Compensation
  • Thomas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Thomas's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Kewaunee Scientific management team in years:

1.8
Average Tenure
43
Average Age
  • The average tenure for the Kewaunee Scientific management team is less than 2 years, this suggests a new team.
Management Team

Thomas Hull

TITLE
President
COMPENSATION
$517K
AGE
43
TENURE
0.3 yrs

Don Gardner

TITLE
VP of Finance
AGE
40
TENURE
0.3 yrs

Elizabeth Phillips

TITLE
Vice President of Human Resources
AGE
42
TENURE
10.1 yrs

Sathya Sathyamurthy

TITLE
MD of International Operations & VP of Kewaunee Scientific Corporation Singapore Pte. Ltd.
AGE
50

Keith Smith

TITLE
Director of Metal Plant Operations and Facilities
COMPENSATION
$260K
AGE
50
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Kewaunee Scientific board of directors in years:

5.2
Average Tenure
63
Average Age
  • The tenure for the Kewaunee Scientific board of directors is about average.
Board of Directors

David Rhind

TITLE
Chairman
COMPENSATION
$106K
AGE
56
TENURE
0.4 yrs

Thomas Hull

TITLE
President
COMPENSATION
$517K
AGE
43
TENURE
0.3 yrs

Margaret Pyle

TITLE
Director
COMPENSATION
$82K
AGE
67
TENURE
24.4 yrs

Don Shaw

TITLE
Director
COMPENSATION
$100K
AGE
68
TENURE
6.1 yrs

Keith Gehl

TITLE
Director
COMPENSATION
$106K
AGE
60
TENURE
4.3 yrs

John Russell

TITLE
Director
COMPENSATION
$90K
AGE
66
TENURE
8.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Mar 19 Buy Ryan Noble Individual 15. Mar 19 15. Mar 19 232 $21.41 $4,967
X
Management checks
We assess Kewaunee Scientific's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kewaunee Scientific has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

KEQU News

Simply Wall St News

Introducing Kewaunee Scientific (NASDAQ:KEQU), The Stock That Dropped 45% In The Last Year

That downside risk was realized by Kewaunee Scientific Corporation (NASDAQ:KEQU) shareholders over the last year, as the share price declined 45%. … Investors should note that there's a difference between Kewaunee Scientific's total shareholder return (TSR) and its share price change, which we've covered above. … A Different Perspective Kewaunee Scientific shareholders are down 43% for the year (even including dividends), but the market itself is up 8.5%.

Simply Wall St -

Does Kewaunee Scientific Corporation's (NASDAQ:KEQU) P/E Ratio Signal A Buying Opportunity?

Kewaunee Scientific has a price to earnings ratio of 14.02, based on the last twelve months. … Check out our latest analysis for Kewaunee Scientific How Do I Calculate A Price To Earnings Ratio? … The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for Kewaunee Scientific: P/E of 14.02 = $21.51 ÷ $1.53 (Based on the trailing twelve months to January 2019.) Is A High Price-to-Earnings Ratio Good?

Simply Wall St -

Kewaunee Scientific Corporation's (NASDAQ:KEQU) 3.4% Dividend Yield Looks Pretty Interesting

Kewaunee Scientific has been paying dividends for a long time, but for the purpose of this analysis, we only examine the past 10 years of payments. … Dividend Growth Potential While dividend payments have been relatively reliable, it would also be nice if earnings per share (EPS) were growing, as this is essential to maintaining the dividend's purchasing power over the long term. … Conclusion To summarise, shareholders should always check that Kewaunee Scientific's dividends are affordable, that its dividend payments are relatively stable, and that it has decent prospects for growing its earnings and dividend.

Simply Wall St -

How Good Is Kewaunee Scientific Corporation (NASDAQ:KEQU), When It Comes To ROE?

Our data shows Kewaunee Scientific has a return on equity of 8.8% for the last year. … That means that for every $1 worth of shareholders' equity, it generated $0.088 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Why Fundamental Investors Might Love Kewaunee Scientific Corporation (NASDAQ:KEQU)

Kewaunee Scientific Corporation (NASDAQ:KEQU) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of KEQU, it.

Simply Wall St -

Is Kewaunee Scientific Corporation (NASDAQ:KEQU) Creating Value For Shareholders?

To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … What is Return On Capital Employed (ROCE)? … Analysts use this formula to calculate return on capital employed:

Simply Wall St -

Did Changing Sentiment Drive Kewaunee Scientific's (NASDAQ:KEQU) Share Price Down By 35%?

That downside risk was realized by Kewaunee Scientific Corporation (NASDAQ:KEQU) shareholders over the last year, as the share price declined 35%. … Longer term investors have fared much better, since the share price is up 24% in three years. … One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Simply Wall St -

3 Days Left To Cash In On Kewaunee Scientific Corporation (NASDAQ:KEQU) Dividend

On the 25 March 2019, Kewaunee Scientific Corporation (NASDAQ:KEQU) will be paying shareholders an upcoming dividend amount of US$0.19 per share. … Investors looking for higher income-generating stocks to add to their portfolio should keep reading, as I examine Kewaunee Scientific's latest financial data to analyse its dividend characteristics. … Will the company be able to keep paying dividend based on the future earnings growth

Simply Wall St -

Kewaunee Scientific Corporation (NASDAQ:KEQU): Time For A Financial Health Check

Kewaunee Scientific Corporation (NASDAQ:KEQU) is a small-cap stock with a market capitalization of US$87m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Does Kewaunee Scientific Corporation (NASDAQ:KEQU) Have A Good P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Kewaunee Scientific has a P/E ratio of 16.84, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

KEQU Company Info

Description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates in two segments, Domestic and International. Its products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. The company’s laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.

Details
Name: Kewaunee Scientific Corporation
KEQU
Exchange: NasdaqGM
Founded: 1906
$51,198,292
2,750,009
Website: http://www.kewaunee.com
Address: Kewaunee Scientific Corporation
2700 West Front Street,
Statesville,
North Carolina, 28677,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM KEQU Common Stock Nasdaq Global Market US USD 02. Jan 1980
Number of employees
Current staff
Staff numbers
856
Kewaunee Scientific employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 23:40
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/06/18
Last earnings filing: 2019/07/11
Last earnings reported: 2019/04/30
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.